Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial
- PMID: 21115589
- PMCID: PMC2993045
- DOI: 10.1136/bmj.c6273
Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial
Abstract
Objective: To investigate whether dietary supplementation with B vitamins or omega 3 fatty acids, or both, could prevent major cardiovascular events in patients with a history of ischaemic heart disease or stroke.
Design: Double blind, randomised, placebo controlled trial; factorial design.
Setting: Recruitment throughout France via a network of 417 cardiologists, neurologists, and other physicians.
Participants: 2501 patients with a history of myocardial infarction, unstable angina, or ischaemic stroke.
Intervention: Daily dietary supplement containing 5-methyltetrahydrofolate (560 μg), vitamin B-6 (3 mg), and vitamin B-12 (20 μg) or placebo; and containing omega 3 fatty acids (600 mg of eicosapentanoic acid and docosahexaenoic acid at a ratio of 2:1) or placebo. Median duration of supplementation was 4.7 years.
Main outcome measures: Major cardiovascular events, defined as a composite of non-fatal myocardial infarction, stroke, or death from cardiovascular disease.
Results: Allocation to B vitamins lowered plasma homocysteine concentrations by 19% compared with placebo, but had no significant effects on major vascular events (75 v 82 patients, hazard ratio, 0.90 (95% confidence interval 0.66 to 1.23, P=0.50)). Allocation to omega 3 fatty acids increased plasma concentrations of omega 3 fatty acids by 37% compared with placebo, but also had no significant effect on major vascular events (81 v 76 patients, hazard ratio 1.08 (0.79 to 1.47, P=0.64)).
Conclusion: This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event.
Trial registration: Current Controlled Trials ISRCTN41926726.
Conflict of interest statement
Competing interests: All authors have completed the Unified Competing Interest form at
Figures
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787959/bin/galp793992.f1_default.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787959/bin/galp793992.f2_default.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787959/bin/galp793992.f3_default.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787959/bin/galp793992.f4_default.gif)
Similar articles
-
Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.Cardiovasc Res. 2023 Jun 13;119(6):1297-1309. doi: 10.1093/cvr/cvac172. Cardiovasc Res. 2023. PMID: 36378553 Free PMC article. Review.
-
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.Lancet Neurol. 2012 Jun;11(6):512-20. doi: 10.1016/S1474-4422(12)70091-1. Epub 2012 May 2. Lancet Neurol. 2012. PMID: 22554931 Free PMC article. Clinical Trial.
-
Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.Arch Intern Med. 2012 May 14;172(9):686-94. doi: 10.1001/archinternmed.2012.262. Arch Intern Med. 2012. PMID: 22493407 Review.
-
Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial.Am J Clin Nutr. 2011 Jul;94(1):278-86. doi: 10.3945/ajcn.110.006320. Epub 2011 May 18. Am J Clin Nutr. 2011. PMID: 21593490 Clinical Trial.
-
B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.Lancet Neurol. 2010 Sep;9(9):855-65. doi: 10.1016/S1474-4422(10)70187-3. Epub 2010 Aug 3. Lancet Neurol. 2010. PMID: 20688574 Clinical Trial.
Cited by
-
Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study.BMJ Med. 2024 May 21;3(1):e000451. doi: 10.1136/bmjmed-2022-000451. eCollection 2024. BMJ Med. 2024. PMID: 38800667 Free PMC article.
-
Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.J Am Heart Assoc. 2024 Feb 20;13(4):e030714. doi: 10.1161/JAHA.123.030714. Epub 2024 Feb 7. J Am Heart Assoc. 2024. PMID: 38323514 Free PMC article.
-
Assessing Health and Economic Benefits of Omega-3 Fatty Acid Supplementation on Cardiovascular Disease in the Republic of Korea.Healthcare (Basel). 2023 Aug 21;11(16):2365. doi: 10.3390/healthcare11162365. Healthcare (Basel). 2023. PMID: 37628562 Free PMC article.
-
The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications.J Clin Med. 2023 May 30;12(11):3758. doi: 10.3390/jcm12113758. J Clin Med. 2023. PMID: 37297952 Free PMC article. Review.
-
Potential Benefits of Omega-3 Polyunsaturated Fatty Acids (N3PUFAs) on Cardiovascular Health Associated with COVID-19: An Update for 2023.Metabolites. 2023 May 5;13(5):630. doi: 10.3390/metabo13050630. Metabolites. 2023. PMID: 37233671 Free PMC article. Review.
References
-
- Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893-6. - PubMed
-
- Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-64. - PubMed
-
- Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002;287:1815-21. - PubMed
-
- Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8. - PubMed
-
- Erkkilä AT, Lehto S, Pyörälä K, Uusitupa MI. n-3 Fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. Am J Clin Nutr 2003;78:65-71. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical